Regeneron Pharmaceuticals (NASDAQ: REGN) insider transactions
In the twelve months to 10 November 2026, executives and directors of Regeneron Pharmaceuticals reported 134 open-market sales of 63,014 shares ($57.9m) and 0 open-market purchases, by 11 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 4 November 2026 | Pitofsky Jason | SVP Controller | Option exercise | +1,500 | $726.53 | 5,772 | Form 4 |
| 4 November 2026 | Pitofsky Jason | SVP Controller | Option exercise | +1,478 | $644.54 | 7,250 | Form 4 |
| 4 November 2026 | Pitofsky Jason | SVP Controller | Open-market sale | −179 | $950.76 | 0 | Form 4 |
| 4 November 2026 | Pitofsky Jason | SVP Controller | Option exercise | +905 | $492.00 | 8,155 | Form 4 |
| 4 November 2026 | Pitofsky Jason | SVP Controller | Open-market sale | −439 | $939.57 | 7,716 | Form 4 |
| 4 November 2026 | Pitofsky Jason | SVP Controller | Open-market sale | −575 | $940.46 | 7,141 | Form 4 |
| 4 November 2026 | Pitofsky Jason | SVP Controller | Open-market sale | −982 | $941.58 | 6,159 | Form 4 |
| 4 November 2026 | Pitofsky Jason | SVP Controller | Open-market sale | −1,215 | $942.31 | 4,944 | Form 4 |
| 4 November 2026 | Pitofsky Jason | SVP Controller | Open-market sale | −529 | $943.53 | 4,415 | Form 4 |
| 4 November 2026 | Pitofsky Jason | SVP Controller | Open-market sale | −108 | $944.22 | 4,307 | Form 4 |
| 4 November 2026 | Pitofsky Jason | SVP Controller | Open-market sale | −35 | $945.61 | 4,272 | Form 4 |
| 3 November 2026 | Zoghbi Huda Y | Director | Option exercise | +7,439 | $380.95 | 9,142 | Form 4 |
| 3 November 2026 | Zoghbi Huda Y | Director | Open-market sale | −6,939 | $970.42 | 2,203 | Form 4 |
| 3 November 2026 | Zoghbi Huda Y | Director | Open-market sale | −500 | $971.06 | 1,703 | Form 4 |
| 3 November 2026 | Murphy Andrew J | Co-Chief Scientific Officer | Gift | −1,054 | — | 46,779 | Form 4 |
| 2 November 2026 | Poon Christine A | Director | Option exercise | +7,830 | $376.69 | 13,049 | Form 4 |
| 2 November 2026 | Poon Christine A | Director | Open-market sale | −218 | $966.74 | 12,831 | Form 4 |
| 2 November 2026 | Poon Christine A | Director | Open-market sale | −772 | $967.38 | 12,059 | Form 4 |
| 2 November 2026 | Poon Christine A | Director | Open-market sale | −2,499 | $968.58 | 9,560 | Form 4 |
| 2 November 2026 | Poon Christine A | Director | Open-market sale | −3,203 | $969.50 | 6,357 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Regeneron Pharmaceuticals page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.